Analysis of the safety and feasibility of sleeve resection under UniVATS after neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type non-small cell lung cancer
Abstract Objective To investigate the safety and feasibility of sleeve resection under Uni-VATS following neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type non-small cell lung cancer(NSCLC). Methods We analyzed 10 cIIB-IIIB NSCLC patients who underwent sleeve lun...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12957-024-03462-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849772468379582464 |
|---|---|
| author | Bo Yang Li-Wen Zhang Yu Zhou Yang-Yun Li Gui-Dong Shi Hao Yang Yue Zhang Cheng-Cheng Zhang Mao-Yong Fu |
| author_facet | Bo Yang Li-Wen Zhang Yu Zhou Yang-Yun Li Gui-Dong Shi Hao Yang Yue Zhang Cheng-Cheng Zhang Mao-Yong Fu |
| author_sort | Bo Yang |
| collection | DOAJ |
| description | Abstract Objective To investigate the safety and feasibility of sleeve resection under Uni-VATS following neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type non-small cell lung cancer(NSCLC). Methods We analyzed 10 cIIB-IIIB NSCLC patients who underwent sleeve lung resection under single-port thoracoscopy from December 2022 to August 2023 after receiving platinum-based chemotherapy combined with albumin paclitaxel and programmed cell death protein-1 (PD-1) inhibitor drugs. Perioperative clinical data, side effects during neoadjuvant therapy, operation time, intraoperative blood loss, conversion rate to open thoracotomy, postoperative duration of chest tube placement, postoperative drainage volume, postoperative complications, and tumor outcomes were recorded. Results This study included 10 patients. The preoperative clinical staging distribution was as follows: Stage IIB, 1 case; Stage IIIA, 5 cases; and Stage IIIB, 4 cases. Imaging evaluation after neoadjuvant therapy revealed that none of the patients achieved complete remission, whereas partial remission and stable disease were observed in 7 cases and 3 cases, respectively. All patients successfully underwent surgery, of which 2 patients required conversion to open thoracotomy (conversion rate, 20%) and 8 patients underwent single-port thoracoscopic minimally invasive surgery. Notably, 2 patients underwent sleeve resection of the right upper lobe, 2 patients underwent sleeve resection of the right middle and lower lobes, 2 patients underwent sleeve resection of the left upper lobe, and 4 patients underwent sleeve resection of the left lower lobe. The average operation time was 236 ± 87.7 min, the average intraoperative blood loss was 168 ± 62.5 mL, the average duration of chest tube placement was 5 days, the average total drainage volume was 1012 ± 464 mL, and the average hospitalization duration was 7 days. One patient developed encapsulated pleural effusion after surgery and underwent computed tomography (CT)-guided puncture drainage. At the 3-month and 6-month follow-up visits, no patient reported any particular discomfort, and chest radiography and CT revealed no abnormalities or signs of tumor recurrence. Conclusion Sleeve resection after neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type NSCLC under single-port thoracoscopy is safe and feasible and provides short-term postoperative benefits for patients. |
| format | Article |
| id | doaj-art-d014e34251ff41f7ad810dcca73c17d8 |
| institution | DOAJ |
| issn | 1477-7819 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | BMC |
| record_format | Article |
| series | World Journal of Surgical Oncology |
| spelling | doaj-art-d014e34251ff41f7ad810dcca73c17d82025-08-20T03:02:19ZengBMCWorld Journal of Surgical Oncology1477-78192025-03-012311710.1186/s12957-024-03462-xAnalysis of the safety and feasibility of sleeve resection under UniVATS after neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type non-small cell lung cancerBo Yang0Li-Wen Zhang1Yu Zhou2Yang-Yun Li3Gui-Dong Shi4Hao Yang5Yue Zhang6Cheng-Cheng Zhang7Mao-Yong Fu8Department of Thoracic Surgery, The Affiliated Hospital of North Sichuan Medical CollegeDepartment of Thoracic Surgery, The Affiliated Hospital of North Sichuan Medical CollegeDepartment of Thoracic Surgery, The Affiliated Hospital of North Sichuan Medical CollegeDepartment of Thoracic Surgery, The Affiliated Hospital of North Sichuan Medical CollegeDepartment of Thoracic Surgery, The Affiliated Hospital of North Sichuan Medical CollegeDepartment of Thoracic Surgery, The Affiliated Hospital of North Sichuan Medical CollegeDepartment of Thoracic Surgery, The Affiliated Hospital of North Sichuan Medical CollegeDepartment of Thoracic Surgery, The Affiliated Hospital of North Sichuan Medical CollegeDepartment of Thoracic Surgery, The Affiliated Hospital of North Sichuan Medical CollegeAbstract Objective To investigate the safety and feasibility of sleeve resection under Uni-VATS following neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type non-small cell lung cancer(NSCLC). Methods We analyzed 10 cIIB-IIIB NSCLC patients who underwent sleeve lung resection under single-port thoracoscopy from December 2022 to August 2023 after receiving platinum-based chemotherapy combined with albumin paclitaxel and programmed cell death protein-1 (PD-1) inhibitor drugs. Perioperative clinical data, side effects during neoadjuvant therapy, operation time, intraoperative blood loss, conversion rate to open thoracotomy, postoperative duration of chest tube placement, postoperative drainage volume, postoperative complications, and tumor outcomes were recorded. Results This study included 10 patients. The preoperative clinical staging distribution was as follows: Stage IIB, 1 case; Stage IIIA, 5 cases; and Stage IIIB, 4 cases. Imaging evaluation after neoadjuvant therapy revealed that none of the patients achieved complete remission, whereas partial remission and stable disease were observed in 7 cases and 3 cases, respectively. All patients successfully underwent surgery, of which 2 patients required conversion to open thoracotomy (conversion rate, 20%) and 8 patients underwent single-port thoracoscopic minimally invasive surgery. Notably, 2 patients underwent sleeve resection of the right upper lobe, 2 patients underwent sleeve resection of the right middle and lower lobes, 2 patients underwent sleeve resection of the left upper lobe, and 4 patients underwent sleeve resection of the left lower lobe. The average operation time was 236 ± 87.7 min, the average intraoperative blood loss was 168 ± 62.5 mL, the average duration of chest tube placement was 5 days, the average total drainage volume was 1012 ± 464 mL, and the average hospitalization duration was 7 days. One patient developed encapsulated pleural effusion after surgery and underwent computed tomography (CT)-guided puncture drainage. At the 3-month and 6-month follow-up visits, no patient reported any particular discomfort, and chest radiography and CT revealed no abnormalities or signs of tumor recurrence. Conclusion Sleeve resection after neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type NSCLC under single-port thoracoscopy is safe and feasible and provides short-term postoperative benefits for patients.https://doi.org/10.1186/s12957-024-03462-xNon-small cell lung cancer(NSCLC)Sleeve resectionNeoadjuvant chemotherapy |
| spellingShingle | Bo Yang Li-Wen Zhang Yu Zhou Yang-Yun Li Gui-Dong Shi Hao Yang Yue Zhang Cheng-Cheng Zhang Mao-Yong Fu Analysis of the safety and feasibility of sleeve resection under UniVATS after neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type non-small cell lung cancer World Journal of Surgical Oncology Non-small cell lung cancer(NSCLC) Sleeve resection Neoadjuvant chemotherapy |
| title | Analysis of the safety and feasibility of sleeve resection under UniVATS after neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type non-small cell lung cancer |
| title_full | Analysis of the safety and feasibility of sleeve resection under UniVATS after neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type non-small cell lung cancer |
| title_fullStr | Analysis of the safety and feasibility of sleeve resection under UniVATS after neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type non-small cell lung cancer |
| title_full_unstemmed | Analysis of the safety and feasibility of sleeve resection under UniVATS after neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type non-small cell lung cancer |
| title_short | Analysis of the safety and feasibility of sleeve resection under UniVATS after neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type non-small cell lung cancer |
| title_sort | analysis of the safety and feasibility of sleeve resection under univats after neoadjuvant chemotherapy combined with immunotherapy for locally advanced central type non small cell lung cancer |
| topic | Non-small cell lung cancer(NSCLC) Sleeve resection Neoadjuvant chemotherapy |
| url | https://doi.org/10.1186/s12957-024-03462-x |
| work_keys_str_mv | AT boyang analysisofthesafetyandfeasibilityofsleeveresectionunderunivatsafterneoadjuvantchemotherapycombinedwithimmunotherapyforlocallyadvancedcentraltypenonsmallcelllungcancer AT liwenzhang analysisofthesafetyandfeasibilityofsleeveresectionunderunivatsafterneoadjuvantchemotherapycombinedwithimmunotherapyforlocallyadvancedcentraltypenonsmallcelllungcancer AT yuzhou analysisofthesafetyandfeasibilityofsleeveresectionunderunivatsafterneoadjuvantchemotherapycombinedwithimmunotherapyforlocallyadvancedcentraltypenonsmallcelllungcancer AT yangyunli analysisofthesafetyandfeasibilityofsleeveresectionunderunivatsafterneoadjuvantchemotherapycombinedwithimmunotherapyforlocallyadvancedcentraltypenonsmallcelllungcancer AT guidongshi analysisofthesafetyandfeasibilityofsleeveresectionunderunivatsafterneoadjuvantchemotherapycombinedwithimmunotherapyforlocallyadvancedcentraltypenonsmallcelllungcancer AT haoyang analysisofthesafetyandfeasibilityofsleeveresectionunderunivatsafterneoadjuvantchemotherapycombinedwithimmunotherapyforlocallyadvancedcentraltypenonsmallcelllungcancer AT yuezhang analysisofthesafetyandfeasibilityofsleeveresectionunderunivatsafterneoadjuvantchemotherapycombinedwithimmunotherapyforlocallyadvancedcentraltypenonsmallcelllungcancer AT chengchengzhang analysisofthesafetyandfeasibilityofsleeveresectionunderunivatsafterneoadjuvantchemotherapycombinedwithimmunotherapyforlocallyadvancedcentraltypenonsmallcelllungcancer AT maoyongfu analysisofthesafetyandfeasibilityofsleeveresectionunderunivatsafterneoadjuvantchemotherapycombinedwithimmunotherapyforlocallyadvancedcentraltypenonsmallcelllungcancer |